Figure 5. Validation of the epigenetic biosignature in the test set. (A) Rankings for the risk signature and group distribution. (B) Heatmap of the gene-expression profiles. Patients in the high-risk group demonstrated (C) earlier mortality and (D) earlier relapse. (E) OS and (F) RFS of patients in the low- and high-risk groups. ROC analyses of (G) OS and (H) RFS predictions using the epigenetic signature.